Related Experiment Video

Updated: May 21, 2026

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Trial Watch: Monoclonal antibodies in cancer therapy

Lorenzo Galluzzi1, Erika Vacchelli, Wolf Hervé Fridman

  • 1INSERM, U848; Villejuif, France ; Institut Gustave Roussy; Villejuif, France ; Université Paris-Sud/Paris XI; Le Kremlin-Bicêtre, France.

Oncoimmunology
|June 22, 2012
PubMed

Insights

Monoclonal antibodies (mAbs) are vital tools in cancer therapy, with new immunostimulatory types entering clinical trials to enhance immune responses against tumors. This review covers key mAbs in trials since 2008.

Area of Science:

  • Immunology
  • Oncology
  • Biotechnology

Background:

  • Monoclonal antibodies (mAbs) have been crucial in diagnostics and therapeutics since 1975.
  • FDA has approved several mAbs for cancer therapy over the last 15 years.
  • mAbs target cancer via immune activation, pathway inhibition, targeted toxin delivery, or stroma interaction.

Purpose of the Study:

  • To review and discuss the clinical progress of significant monoclonal antibodies (mAbs).
  • Focus on mAbs that entered clinical trials after January 2008.
  • Highlight the development of immunostimulatory mAbs for cancer treatment.

Main Methods:

  • Literature review of clinical trial data.
  • Analysis of FDA-approved monoclonal antibodies (mAbs).
  • Focus on recent advancements in immunostimulatory antibody development.

Main Results:

  • Monoclonal antibodies (mAbs) are increasingly used in cancer therapy.
  • Newer mAbs aim to enhance anti-tumor immune responses.
  • Several immunostimulatory mAbs are progressing through clinical trials.

Conclusions:

  • Monoclonal antibodies (mAbs) continue to be a cornerstone of modern cancer therapy.
  • Immunostimulatory mAbs represent a promising frontier in cancer treatment.
  • Ongoing clinical trials are evaluating the efficacy of novel mAbs for tumor eradication.

More Related Videos

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research08:53

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis07:40

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...